ライフサイエンスコーパス: bronchiectasis

1 curred later, and lung disease was moderate (bronchiectasis).

2 8.15 (95% CI 3.59-18.5) for lung abscess or bronchiectasis.

3 onchiectasis, ANCA-associated vasculitis and bronchiectasis.

4 tality and disease outcomes in patients with bronchiectasis.

5 ive value (50-55%) to detect the presence of bronchiectasis.

6 alities, pulmonary arterial enlargement, and bronchiectasis.

7 the brother was fairly asymptomatic but had bronchiectasis.

8 clinical and research tool in patients with bronchiectasis.

9 on, and increased mortality in patients with bronchiectasis.

10 nti-inflammatory treatment for patients with bronchiectasis.

11 icrobiota in people with non-cystic fibrosis bronchiectasis.

12 om 53 of 842 (6.3%) to 53 of 1465 (3.6%) for bronchiectasis.

13 ronic respiratory infections associated with bronchiectasis.

14 vastatin could reduce cough in patients with bronchiectasis.

15 n of respiratory microbiota in patients with bronchiectasis.

16 bronchial thickening, pleural thickening and bronchiectasis.

17 on a quality-of-life scale in patients with bronchiectasis.

18 ication tools for morbidity and mortality in bronchiectasis.

19 er findings also suggest a benefit in non-CF bronchiectasis.

20 t of patients with adult non-cystic fibrosis bronchiectasis.

21 the independent adjusted prognostic value of bronchiectasis.

22 rtant modifier of disease severity in non-CF bronchiectasis.

23 cystic fibrosis, and age-dependent onset of bronchiectasis.

24 y on disease severity in non-cystic fibrosis bronchiectasis.

25 ession, predicting lung function decline and bronchiectasis.

26 c role for S. mucilaginosus in patients with bronchiectasis.

27 is in patients with non-cystic fibrosis (CF) bronchiectasis.

28 ung infection, particularly in patients with bronchiectasis.

29 , chronic obstructive pulmonary disease, and bronchiectasis.

30 e pulmonary disease, pulmonary fibrosis, and bronchiectasis.

31 atients with cystic fibrosis (CF) and non-CF bronchiectasis.

32 zygosity are associated with the presence of bronchiectasis.

33 tions by genotyping patients with idiopathic bronchiectasis.

34 tion of genetic susceptibility in idiopathic bronchiectasis.

35 nd/or reticular pattern, often with traction bronchiectasis.

36 cular pattern with honeycombing and traction bronchiectasis.

37 utum of a poodle-owning patient with chronic bronchiectasis.

38 that leads to chronic airway obstruction and bronchiectasis.

39 ), and 87% occurred in patients with nodular bronchiectasis.

40 ed from new strains in patients with nodular bronchiectasis.

41 ases also occur in severe COPD as they do in bronchiectasis.

42 inusitis, laryngitis, asthma, pneumonia, and bronchiectasis.

43 ean of only 5 pack-years, and had multifocal bronchiectasis.

44 aride plays an important part, one developed bronchiectasis.

45 er-lobe cavitary disease and 50% had nodular bronchiectasis.

46 nt available for health status assessment in bronchiectasis.

47 of primary granules, before the detection of bronchiectasis.

48 nosinusitis, otitis media with effusion, and bronchiectasis.

49 re prospective studies including adults with bronchiectasis.

50 rent severe respiratory tract infections and bronchiectasis.

51 macrolide antibiotics in adult patients with bronchiectasis.

52 rkers of disease severity and progression in bronchiectasis.

53 ease severity and future risk in adults with bronchiectasis.

54 ss syndrome, pneumonia, cystic fibrosis, and bronchiectasis.

55 h exacerbations and lung function decline in bronchiectasis.

56 , pneumonia (6.3% vs. 2.3%, P < 0.0001), and bronchiectasis (1.0% vs. 0.1%, P < 0.0001).

57 1.27), pulmonary fibrosis (1.36; 1.25-1.48), bronchiectasis (1.26; 1.09-1.47), pulmonary collapse (1.

58 mmunity, 28.6%; chronic lung disease, 28.5%; bronchiectasis, 11.2%; gastrointestinal inflammatory dis

59 ure (4; 14%), limb lymphoedema (3; 10%), and bronchiectasis (2; 7%).

60 Other findings included bronchiectasis (48%), pleural thickening (40%), ground g

61 (P = 0.005)), and an increased frequency of bronchiectasis (54.5%, P < 0.001), tree-in-bud (18.7%, P

62 termine causative factors in 150 adults with bronchiectasis (56 male, 94 female) identified using hig

63 Airway involvement was noted as bronchiectasis (77%) and bronchial stenosis (4%) but non

64 Improving endophenotyping of sensitized bronchiectasis, a clinically significant state, and a "t

65 Bronchiectasis, a syndrome of pathological airway dilati

66 f the 5 year mortality rate to construct the Bronchiectasis Aetiology Comorbidity Index (BACI).

67 In vitro, cystic fibrosis and bronchiectasis airway fluid directly inhibited apoptotic

68 irway.Objectives: To characterize PZP in the bronchiectasis airway, including its relationship with d

69 x-point scale) of emphysema, the presence of bronchiectasis, airway wall thickening, and tracheal abn

70 linical outcomes in non-cystic fibrosis (CF) bronchiectasis, although associated risks of macrolide r

71 ic virus 1 (HTLV-1) might be associated with bronchiectasis among Indigenous Australians.

72 tment of cystic fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiec

73 omic DNA from 96 individuals with idiopathic bronchiectasis and 101 control subjects was analyzed by

74 four (47%) patients had nodular disease with bronchiectasis and 27 (53%) had upper lobe cavitary dise

75 Netherlands among 83 outpatients with non-CF bronchiectasis and 3 or more lower respiratory tract inf

76 We included 470 patients with bronchiectasis and 414 controls.

77 recruited patients with non-cystic fibrosis bronchiectasis and age-matched and sex-matched controls

78 ) in adult patients with non-cystic fibrosis bronchiectasis and at least two infective exacerbations

79 Multimorbidity is frequent in bronchiectasis and can negatively affect survival.

80 tem spleen sample of a woman presenting with bronchiectasis and cavitary lung disease associated with

81 fibrosis (CF) lung disease as well as non-CF bronchiectasis and chronic obstructive airways disease.

82 In patients with non-cystic fibrosis bronchiectasis and chronic P aeruginosa lung infection r

83 Patients with bronchiectasis and chronic P. aeruginosa infection were

84 ffective treatment in adherent patients with bronchiectasis and chronic P. aeruginosa infection.

85 nhaled-antibiotic use in adult patients with bronchiectasis and chronic respiratory tract infections.

86 ovements in quality of life in patients with bronchiectasis and chronic respiratory tract infections.

87 s for the long-term treatment of adults with bronchiectasis and chronic respiratory tract infections.

88 Medicines Initiative inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis Consortium, European

89 hickening, airway smooth muscle hypertrophy, bronchiectasis and emphysema.

90 ith chronic tobacco use and is causative for bronchiectasis and emphysema.

91 o investigate comorbidities in patients with bronchiectasis and establish their prognostic value on d

92 causing symptoms such as chronic sinusitis, bronchiectasis and frequently SIT.

93 (AZLI) in patients with non-cystic fibrosis bronchiectasis and Gram-negative bacterial colonisation.

94 UC5B rs35705950 SNP allele frequency between bronchiectasis and healthy individuals.

95 Such infections are associated with bronchiectasis and high mortality rates, making them a s

96 uded patients aged 18 years or older who had bronchiectasis and history of positive sputum or broncho

97 ctive cohort study of Indigenous adults with bronchiectasis and known HTLV-1 serologic status admitte

98 DESIGN, SETTING, AND PARTICIPANTS: The BAT (Bronchiectasis and Long-term Azithromycin Treatment) stu

99 o information about the relationship between bronchiectasis and mortality in patients with COPD is cu

100 nto the heterogeneity of non-cystic fibrosis bronchiectasis and optimal outcome measures for inhaled

101 at in a significant portion of patients with bronchiectasis and Pseudomonas aeruginosa lung infection

102 5) was the most frequent underlying cause of bronchiectasis and Pseudomonas aeruginosa was the most c

103 ed tobramycin for treatment of patients with bronchiectasis and Pseudomonas aeruginosa.

104 and early-onset pulmonary disease including bronchiectasis and pulmonary emphysema.

105 ota is present in the lungs of patients with bronchiectasis and remains stable through treatment of e

106 tion and inflammation leading to progressive bronchiectasis and respiratory failure.

107 and personalized microbiome in patients with bronchiectasis and suggest a pathogenic role for S. muci

108 s structural pulmonary abnormalities such as bronchiectasis and trapped air, at an early stage, befor

109 ection contributes to the risk of developing bronchiectasis and worsens outcomes among Indigenous Aus

110 for ground-glass opacity, reticulation, and bronchiectasis and/or bronchiolectasis and (b) identical

111 nts were treated with ICS, 57.2% of them had bronchiectasis, and 20.9% had <100 blood eosinophils/mul

112 Many patients develop central bronchiectasis, and a subset will go on to endstage fibr

113 (GGO), reticulation, honeycombing, nodules, bronchiectasis, and air trapping were assessed retrospec

114 dex correlates with extent of total disease, bronchiectasis, and air trapping.

115 ry diseases such as asthma, cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary diseas

116 ngs of extensive reticular pattern, traction bronchiectasis, and honeycombing are closely related to

117 increased total IgE and specific IgE levels, bronchiectasis, and mold colonization of the airways.

118 rom several cancers, ischemic heart disease, bronchiectasis, and other diseases.

119 the disease outcomes, such as development of bronchiectasis, anogenital dysplasia, or invasive cancer

120 ed odds ratio [aOR] 5.65, 95% CI 5.52-5.79), bronchiectasis (aOR 4.65, 95% CI 4.26-5.08), eczema/psor

121 In one of the girls, bronchiectasis appeared at follow-up.

122 High airway bacterial loads in non-CF bronchiectasis are associated with airway and systemic i

123 els to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorit

124 number of therapies for non-cystic fibrosis bronchiectasis are undergoing testing in clinical resear

125 riers (e.g., pancreatitis, male infertility, bronchiectasis), as well as some conditions not previous

126 cant clinical benefit in non-cystic fibrosis bronchiectasis, as measured by QOL-B-RSS, suggesting a c

127 Underlying aetiology of bronchiectasis, as well as treatment and risk factors fo

128 hiectasis due to cystic fibrosis or traction bronchiectasis associated with another respiratory disor

129 screened in familial pulmonary diseases with bronchiectasis, associated with a medical history of vis

130 es that commonly involve bronchioles include bronchiectasis, asthma, and chronic obstructive pulmonar

131 hronic obstructive pulmonary disease (COPD), bronchiectasis, asthma, and lung cancer.

132 are increased in the sputum of patients with bronchiectasis at baseline and increase further during e

133 The point prevalence of bronchiectasis at each visit increased from 29.3% at 3 m

134 e collected through the European Multicentre Bronchiectasis Audit and Research Collaboration registry

135 with or without malabsorption, but not with bronchiectasis, autoimmunity, other cancers, granulomato

136 sa infection in cystic fibrosis (CF), non-CF bronchiectasis (BE), and chronic obstructive pulmonary d

137 otracted bacterial bronchitis (PBB) and mild bronchiectasis (BE).

138 low limitation and radiologically determined bronchiectasis/bronchiolitis, respectively, and 5.21 (1.

139 tibiotic therapy can be initiated to prevent bronchiectasis, but also to avoid inappropriate immunosu

140 prevent exacerbations in adult patients with bronchiectasis, but these individual studies have been t

141 eparate proportions of total disease (%Dis), bronchiectasis (%Bx), and trapped air (%TA) were determi

142 alities including bronchial wall thickening, bronchiectasis, centrilobular opacities, and air trappin

143 ts with cystic fibrosis, non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, a

144 establish chronic respiratory infections in bronchiectasis, chronic obstructive pulmonary disease, a

145 Tree-in-bud, ground-glass-opacity, bronchiectasis, cicatricial emphysema, and lobar atelect

146 hed and sex-matched controls at a specialist bronchiectasis clinic in Edinburgh, UK.

147 iectasis was associated with improvements in bronchiectasis clinical outcomes.

148 rapy may suffice in certain conditions, like bronchiectasis, coagulopathies, Goodpasture's syndrome,

149 In a replication bronchiectasis cohort, spontaneously expectorated and hy

150 or sputum protein profiling of patients with bronchiectasis confirmed by high-resolution computed tom

151 Eligible patients were those with bronchiectasis confirmed by high-resolution CT and a com

152 Bronchiectasis develops early in the course of cystic fi

153 uded if the patients were adults with stable bronchiectasis diagnosed by CT or bronchography, the tri

154 significantly associated with development of bronchiectasis (difference, 0.9; 95% confidence interval

155 Patients with bronchiectasis due to cystic fibrosis or traction bronch

156 tion, NET formation, and disease severity in bronchiectasis during chronic airway inflammation.

157 rial infections of the respiratory tract and bronchiectasis, even with adequate immunoglobulin replac

158 rm and had a primary or secondary outcome of bronchiectasis exacerbations.

159 zation to multiple allergens was detected in bronchiectasis, exceeding that in a comparator cohort wi

160 patient with a history of asthma and chronic bronchiectasis experiencing right-middle-lobe syndrome g

161 ed inversely with FEV(1) and positively with bronchiectasis extent, as measured by high-resolution co

162 isk factors associated with the detection of bronchiectasis from 3 months to 3 years of age.

163 ticentre cohort analysis of outpatients with bronchiectasis from four European centres followed up fo

164 airways of patients with cystic fibrosis or bronchiectasis from other causes and appears to have evo

165 ange, 1 to 9) were identified in the nodular bronchiectasis group, with 15 of 17 patients (88%) havin

166 rrent bacterial and candidal infections with bronchiectasis, growth delay, and early death.

167 Bronchiectasis guidelines recommend long-term macrolide

168 Patients with bronchiectasis had higher levels of airway inflammatory

169 55 (12%) patients with bronchiectasis had low-expressing genotypes.

170 Patients with bronchiectasis had significantly higher infection scores

171 Eligible patients had non-cystic fibrosis bronchiectasis, had had at least two pulmonary exacerbat

172 f inhaled antibiotics in non-cystic fibrosis bronchiectasis has not been established in randomised co

173 Patients with bronchiectasis have frequent exacerbations that are thou

174 data demonstrate that patients with nodular bronchiectasis have multiple and/or repeated infections

175 presented with recurrent infections, eczema, bronchiectasis, high IgE, eosinophilia, defective B cell

176 attern and were more likely to have traction bronchiectasis, honeycombing, and a UIP pattern than tho

177 ), chronic obstructive pulmonary disease and bronchiectasis (HR 1.55, 95 % CI: 1.17-2.04), malnutriti

178 cient , 0.96) with regard to the severity of bronchiectasis ( ICC intraclass correlation coefficient

179 Participants had clinically significant bronchiectasis (ie, cough and sputum production when cli

180 culation, tiny nodules, altered attenuation, bronchiectasis), image quality (graded by using a six-po

181 viduals with cystic fibrosis (CF) and non-CF bronchiectasis, impacting morbidity and mortality.

182 The severity of bronchiectasis in children with cystic fibrosis is signi

183 luid in early life was associated with early bronchiectasis in children with cystic fibrosis.

184 Patients with bronchiectasis in India have more severe disease and hav

185 to improve quality of care for patients with bronchiectasis in India.

186 microbiology, and treatment of patients with bronchiectasis in India.

187 the clinical characteristics and outcomes of bronchiectasis in this population, according to HTLV-1 s

188 lace chest computed tomography to screen for bronchiectasis in this population.

189 ng chronic obstructive pulmonary disease and bronchiectasis in women, are associated with solid fuel

190 Bronchiectasis is a common but neglected chronic lung di

191 Bronchiectasis is a disorder of persistent lung inflamma

192 Bronchiectasis is a pathologic description of lung damag

193 Bronchiectasis is characterised by chronic cough, sputum

194 Rationale: Non-cystic fibrosis bronchiectasis is characterized by airway mucus accumula

195 The prevalence of bronchiectasis is high in patients with moderate-to-seve

196 he long-term treatment of chronic asthma and bronchiectasis is less well established.

197 l underlying inhaled antibiotic treatment in bronchiectasis is that airway bacterial load drives infl

198 remodeling (healed cavitation, fibrosis, and bronchiectasis) is a major cause of lung disability, sur

199 tigation of this population of patients with bronchiectasis led to identification of one or more caus

200 way mucus is characteristic of subjects with bronchiectasis, likely contributes to disease pathophysi

201 In patients with non-cystic fibrosis bronchiectasis, lung infection with Pseudomonas aerugino

202 istent with changes observed in CF and other bronchiectasis lungs.

203 ce of apoptotic cells in cystic fibrosis and bronchiectasis may be due to elastase-mediated cleavage

204 ular lines, lobular distortion, and traction bronchiectasis may occur as the illness evolves.

205 Bronchiectasis may present in autoimmune disease, as wel

206 -year-old IDA/CA/MTD group had more lobes of bronchiectasis (median, 5; P = 0.0008) and consolidation

207 coidosis, such as pulmonary hypertension and bronchiectasis, might also contribute to an increase in

208 rlaid on 10 axial slices for the presence of bronchiectasis, mucous plugging, or other airway abnorma

209 halation acutely reduced non-cystic fibrosis bronchiectasis mucus concentration by 5%.Conclusions: Hy

210 concentration and biophysical properties of bronchiectasis mucus; 2) identify the secreted mucins co

211 2) identify the secreted mucins contained in bronchiectasis mucus; 3) relate mucus properties to airw

212 MRI demonstrated bronchial wall thickening/bronchiectasis, mucus plugging, and perfusion deficits f

213 nce of increased mortality from lung cancer, bronchiectasis, myocardial infarction, and kidney cancer

214 tis obliterans (n=1), sarcoidosis (n=1), and bronchiectasis (n=1).

215 European Bronchiectasis Network (EMBARC).

216 e infections, the sequelae of infection (eg, bronchiectasis), non-infectious immune-mediated manifest

217 use of inhaled antibiotics in patients with bronchiectasis not due to cystic fibrosis.

218 s suggested by the observation that familial bronchiectasis occurs in a rare group of individuals wit

219 -three percent of patients (68 of 82) showed bronchiectasis of varying severity.

220 Patients with bronchiectasis often have concurrent comorbidities, but

221 perfusion, vascular attenuation, and central bronchiectasis on chest high-resolution computed tomogra

222 practice who had possible UIP with traction bronchiectasis on HRCT and had not undergone surgical lu

223 Evidence of moderate lower lobe bronchiectasis on HRCT is common in COPD and is associat

224 Twenty-seven of 54 patients (50%) had bronchiectasis on HRCT, most frequently in the lower lob

225 chest to quantify the presence and extent of bronchiectasis or emphysema.

226 onia (OR, 2.3; CI, 1.8-2.9; P < 0.0001), and bronchiectasis (OR, 2.3; CI, 1.1-4.6; P = 0.0193).

227 aving chronic obstructive pulmonary disease, bronchiectasis, or poor lung function increased symptom

228 ry of chronic obstructive pulmonary disease, bronchiectasis, or previous treatment for MAC-PD.

229 r infection scores than did patients without bronchiectasis (P < .005).

230 with mucoid PA correlated significantly with bronchiectasis (P = .041).

231 primarily by chronic pulmonary infection and bronchiectasis, pancreatic exocrine impairment, and elev

232 from cystic fibrosis and non-cystic fibrosis bronchiectasis patients demonstrated an abundance of apo

233 tudy is warranted to further evaluate TSI in bronchiectasis patients.

234 de that the SGRQ reflects impaired health in bronchiectasis patients.

235 nib if they had honeycombing and/or traction bronchiectasis plus reticulation, without atypical featu

236 months of age was associated with persistent bronchiectasis (present on two or more sequential scans)

237 igh-resolution computed tomography-confirmed bronchiectasis provided blood samples for desmosine meas

238 The scores for neither the Quality of Life Bronchiectasis questionnaire nor St George's Respiratory

239 P < 0.0001), and the radiological extent of bronchiectasis (r = 0.29; P < 0.0001).

240 on occurs at high frequency in patients with bronchiectasis recruited from different global centers.

241 ve cohort study using the TAYBRIDGE (Tayside Bronchiectasis Registry Integrating Datasets, Genomics,

242 The Indian bronchiectasis registry is a multicentre, prospective, o

243 r bronchiectasis were analysed in the Indian bronchiectasis registry.

244 clinical significance in non-cystic fibrosis bronchiectasis remain unclear.

245 cluded chronic obstructive pulmonary disease/bronchiectasis, renal failure, diabetes, depression, and

246 may allow improved stratification in future bronchiectasis research and clinical trials.

247 int was change from baseline Quality of Life-Bronchiectasis Respiratory Symptoms scores (QOL-B-RSS) a

248 ent in the primary endpoint (Quality of Life-Bronchiectasis-Respiratory Symptoms Score at Week 4) in

249 ncluding 325 with PCD and 88 with idiopathic bronchiectasis, revealed biallelic loss-of-function muta

250 resence at age 3, whereas only the change in bronchiectasis score was related to neutrophil elastase

251 ognostic information when used alongside the Bronchiectasis Severity Index (BSI).

252 scribes the derivation and validation of the Bronchiectasis Severity Index (BSI).

253 e activity in sputum was associated with the bronchiectasis severity index (r = 0.49; P < 0.0001) and

254 f PZP were significantly associated with the Bronchiectasis Severity Index, the frequency of exacerba

255 matched recruited patients on age, sex, and bronchiectasis severity.

256 nfection with mucoid PA; attempts to prevent bronchiectasis should include reducing exposure to and e

257 morbidity and mortality is mostly caused by bronchiectasis, small airways obstruction, and progressi

258 ith small airway disease and associated with bronchiectasis (Spearman correlation coefficient (r(2) =

259 were measured.Measurements and Main Results: Bronchiectasis sputum exhibited increased percent solids

260 Within subjects with bronchiectasis, sputum percent solids correlated inverse

261 ticular opacities, volume loss, and traction bronchiectasis superimposed on subacute changes are obse

262 Here we identify a bronchiectasis syndrome caused by mutations that inactiv

263 Among patients with non-CF bronchiectasis, the 12-month use of erythromycin compare

264 Among adults with non-CF bronchiectasis, the daily use of azithromycin for 12 mon

265 In bronchiectasis there is a need for improved markers of l

266 intracellulare from patients with underlying bronchiectasis, to establish a nonsequence-based databas

267 ics, and 34 patients with an exacerbation of bronchiectasis treated with intravenous antibiotics.

268 t to determine risk factors for the onset of bronchiectasis, using data collected by the Australian R

269 versus lung disease, and the development of bronchiectasis versus immune-mediated complications, are

270 Bronchiectasis was associated with an increased risk of

271 Bronchiectasis was associated with an independent increa

272 e activity with brensocatib in patients with bronchiectasis was associated with improvements in bronc

273 Lower lobe bronchiectasis was associated with lower airway bacteria

274 Bronchiectasis was diagnosed by high-resolution computed

275 rmed a set of interrelated features, whereas bronchiectasis was not associated with any other clinica

276 Bronchiectasis was present in 115 (57.2%) patients.

277 A separate group of 60 patients with stable bronchiectasis was studied on a single visit with the sa

278 ll 118 subjects, median number of lobes with bronchiectasis was three and alveolar consolidation was

279 "Sensitized bronchiectasis" was classified into two immunoallertypes

280 In a cohort of 182 subjects with bronchiectasis, we found that 9% were colonized with S.

281 s, as well as treatment and risk factors for bronchiectasis were analysed in the Indian bronchiectasi

282 dult patients (>=18 years) with CT-confirmed bronchiectasis were enrolled from 31 centres across Indi

283 Studies in patients with cystic fibrosis bronchiectasis were excluded.

284 In multivariate analyses, risk factors for bronchiectasis were presentation with meconium ileus (od

285 Thirty patients with stable bronchiectasis were recruited and lung clearance index,

286 Patients with bronchiectasis were recruited in Asia (Singapore and Mal

287 , 2006, and Nov 22, 2013, 1340 patients with bronchiectasis were screened and 986 patients were analy

288 Patients with non-CF bronchiectasis were stratified by frequency of PA isolat

289 tive lung disease, obstructive lung disease, bronchiectasis) were labelled as major sequelae.

290 , chronic obstructive pulmonary disease, and bronchiectasis) were subjected to metagenomic sequencing

291 es in patients with cystic fibrosis, such as bronchiectasis (which is progressive, irreversible and p

292 PD diagnosis increased except for asthma and bronchiectasis, which decreased between 1990 and 2007, f

293 e is renewed interest in non-cystic fibrosis bronchiectasis, which is a cause of significant morbidit

294 ing the Cohort of Asian and Matched European Bronchiectasis, which matched recruited patients on age,

295 ly assigned, in a 1:1:1 ratio, patients with bronchiectasis who had had at least two exacerbations in

296 were collected from 17 patients with nodular bronchiectasis who were elderly (mean age 66 yr), predom

297 ently nonsmoking, adult patients with non-CF bronchiectasis with a history of 2 or more infective exa

298 long-term management of non-cystic fibrosis bronchiectasis with frequent exacerbations, there is no

299 um samples were collected from subjects with bronchiectasis, with and without chronic erythromycin ad

300 frequency of exacerbations in patients with bronchiectasis, with similar benefits observed in all su